← Back to Clinical Trials
Recruiting NCT07027280

NCT07027280 Noninvasive Intratumor Heterogeneity Evaluation in HNSCC

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07027280
Status Recruiting
Phase
Sponsor First Affiliated Hospital of Chongqing Medical University
Condition Head and Neck Cancer
Study Type OBSERVATIONAL
Enrollment 700 participants
Start Date 2025-02-27
Primary Completion 2025-06-15

Eligibility & Interventions

Sex All sexes
Min Age 15 Years
Max Age 89 Years
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 700 participants in total. It began in 2025-02-27 with a primary completion date of 2025-06-15.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This study focuses on tumor heterogeneity, a core challenge in the field of oncology, and innovatively utilizes patient imaging data to deeply mine and analyze intratumoral heterogeneity. By constructing an imaging analysis model for tumor heterogeneity and associating this model with clinical, pathological, transcriptomic, and metabolomic data of patients, a multi-omics decoding of tumor heterogeneity is achieved. The main questions it aims to address are: Can the ITH model stratify patients' treatment efficacy and prognosis assessment? Can pathological and multi-omics sequencing map the mechanisms behind the ITH model?

Eligibility Criteria

Inclusion Criteria: Pathologically confirmed head and neck squamous cell carcinoma (HNSCC). Complete clinical, imaging, and pathological data. Available complete follow-up information. Exclusion Criteria: Patients who received chemotherapy or radiotherapy before surgery. Poor image quality. Tumors too small to be easily identified. History of other concurrent malignant tumors.

Contact & Investigator

Central Contact

xinwei Chen

✉ cxw9977@163.com

📞 +8615178870590

Frequently Asked Questions

Who can join the NCT07027280 clinical trial?

This trial is open to participants of all sexes, aged 15 Years or older, up to 89 Years, studying Head and Neck Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07027280 currently recruiting?

Yes, NCT07027280 is actively recruiting participants. Contact the research team at cxw9977@163.com for enrollment information.

Where is the NCT07027280 trial being conducted?

This trial is being conducted at Chongqing, China.

Who is sponsoring the NCT07027280 clinical trial?

NCT07027280 is sponsored by First Affiliated Hospital of Chongqing Medical University. The trial plans to enroll 700 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology